J&J’s US OTC Sales Hold Firm As COVID Impact Begins To Bite
Executive Summary
Johnson & Johnson US OTC sales a bright spot in a Q2 performance hampered by the COVID-19 pandemic.
You may also be interested in...
US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?
April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.
Band-Aid Covers Sales Driver Role To Continue J&J’s Consumer Health Business Growth
Iconic brand could have spurred consumer interest and helped drive 15.2% US sales growth for its wound care business with the launch earlier in 2020 of strips in hues that better match the skin tones of black and brown customers.
J&J’s Skin-Care Biz During COVID Is ‘Tale of Two Cities’
Johnson & Johnson skin health includes hard-hit products and products that have seen double-digit sales growth during the pandemic, worldwide chairman of Consumer Health Thibaut Mongon said at the Barclays Global Consumer Staples Conference. He went on to highlight launches that are reinforcing J&J’s lead in therapeutic skin care and reflecting its sustainability push.